TBXA2R
Thromboxane A2 receptor
As of the edition of 20 October 2026, TBXA2R (thromboxane A2 receptor, UniProt P21731) has 3 drugs tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21731
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Lungs and airways; Heart and blood vessels; Immune system; Infections
- Registered trials of its drugs
- 7
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Terbogrel | Stopped | Phase 2 | none listed |
| Ramatroban | Stopped | Phase 3 | none listed |
| Picotamide | Marketed | No phase stated | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Boehringer Ingelheim | Route A |
The other 0 companies at TBXA2R
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at TBXA2R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.